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Abstract
De novo mutations affect risk for many diseases and disorders, especially those with early-onset. An example is autism
spectrum disorders (ASD). Four recent whole-exome sequencing (WES) studies of ASD families revealed a handful of novel
risk genes, based on independent de novo loss-of-function (LoF) mutations falling in the same gene, and found that de novo
LoF mutations occurred at a twofold higher rate than expected by chance. However successful these studies were, they
used only a small fraction of the data, excluding other types of de novo mutations and inherited rare variants. Moreover,
such analyses cannot readily incorporate data from case-control studies. An important research challenge in gene discovery,
therefore, is to develop statistical methods that accommodate a broader class of rare variation. We develop methods that
can incorporate WES data regarding de novo mutations, inherited variants present, and variants identified within cases and
controls. TADA, for Transmission And De novo Association, integrates these data by a gene-based likelihood model involving
parameters for allele frequencies and gene-specific penetrances. Inference is based on a Hierarchical Bayes strategy that
borrows information across all genes to infer parameters that would be difficult to estimate for individual genes. In addition
to theoretical development we validated TADA using realistic simulations mimicking rare, large-effect mutations affecting
risk for ASD and show it has dramatically better power than other common methods of analysis. Thus TADA’s integration of
various kinds of WES data can be a highly effective means of identifying novel risk genes. Indeed, application of TADA to
WES data from subjects with ASD and their families, as well as from a study of ASD subjects and controls, revealed several
novel and promising ASD candidate genes with strong statistical support.
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Introduction
The genetic architecture of autism spectrum disorders (ASD) is
complex and thought to involve the action of at least hundreds of
genes. Yet, despite this complexity, four recent studies [1–4]
identified five novel genes affecting the risk for ASD from whole-
exome sequencing (WES) of 932 ASD probands. The studies made
these discoveries by also sequencing the parents of the probands
and thereby discovering a multiplicity of independent Loss-of-
Function (LoF) mutations in each of these five genes. The
multiplicity is key: due to the rarity of de novo LoF events, two or
more independent recurrent events in a sample of this size
generate more evidence for association than would two LoF
variants found in a comparable case and control sample. Thus,
even though de novo events are rare, these observations provide an
excellent signal-to-noise ratio, have proven valuable in the pursuit
of reliable signals for genes affecting the ASD risk, and are likely to
form the foundation for many studies targeting gene discovery in
the future [5].
Note, however, that the multiplicity test is using only a small
fraction of all the information collected by a WES study. Many
other de novo events occur, beyond LoF, and these are ignored.
Moreover it completely ignores inherited rare variants within
families. And, of course, delineation of rare variants into inherited
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and de novo is challenging or impossible for case-control studies. We
conjecture that the distribution of variation, whether inherited, de
novo and from case-control, can be leveraged, in combination with
the de novo mutations, to maximize the statistical power to detect
risk genes.
We propose an integrated model of de novo mutations and
transmitted variation to address these challenges. We demonstrate
that both the number of de novo mutations and the numbers of
different types of transmitted variations in family trios (father,
mother and an affected child), follow simple distributions
dependent on a set of common parameters: mutation rates,
relative risks of mutations and population frequency of the
variants. This model readily incorporates additional data from
case-control studies. The statistical framework of our model
enables us to rigorously analyze the genetic architecture of a
complex disease, conduct power and sample size analysis, and
identify risk genes with higher sensitivity. Through simulations we
show that the power of our novel statistical test, called TADA for
‘‘transmission and de novo association’’, is substantially higher than
competing tests. Our simulations also provide guidance in
planning future studies targeting discovery of genes involved in
the risks of complex diseases, henceforth, risk genes.
We demonstrate the benefits of TADA through an extensive
study of ASD using published WES data from 932 ASD trios as
well as nearly 1000 ASD subjects and matched control subjects
from the ARRA Autism Sequencing Consortium (AASC) study
[6,7]. Using the model underlying TADA, we estimate there are
approximately 1000 genes that play a role in risk for ASD, with an
average relative risk of approximately 20 due to LoF in one of
these genes. Finally, we identify several potential novel ASD risk
genes (genes whose mutations affect the risk of ASD) using TADA
and the ASD data.
Results
Multiplicity test of de novo mutations
For concreteness we start by reviewing the multiplicity test to
detect risk genes by evaluating the independent recurrence of de
novo mutations in the same gene. The multiplicity test classifies a
gene as affecting risk if it sustains d or more recurrent de novo LoF
mutations in a sample of N families. Based on computations of
expected rates of de novo events as a function of a gene’s exonic
length and base pair composition [2], a recent study [1] found that
d§2 LoF events for Nv1000 is significant evidence to declare a
gene as a risk gene (pv0:05, genomewide). Applying this threshold
to data from four ASD family studies [1–4] led to the discovery of
five novel genes affecting ASD risk.
A weakness of the multiplicity test is that it produces a single
threshold for the entire genome, regardless of the heterogeneity
amongst genes in their sizes and base pair composition, and its
threshold is a function of sample size, so that the threshold for
N~1,000 is inadequate when the sample increases to N~10,000.
To illustrate the power of the Multiplicity Test and its properties,
we performed some simulations using genetic parameters that are
described and estimated in the next section.
As demonstrated previously [1], the power for detecting a gene
increases monotonically with increasing sample size N and it
depends strongly on the gene’s mutation rate (Figure 1A).
Although the per gene power is relatively low, for a disorder like
ASD, more than 60 genes are expected to contain at least two LoF
mutations with N~5000 families (Figure 1B). The corresponding
false discovery rate (FDR) is less than 5% for Nv2000 and well
below 10% for N as large as 5,000; switching to a threshold of
d~3 to diminish false discoveries leads to a significant loss in
power (Figure 1B).
The original treatment of the multiplicity test as requiring a
single threshold is simple to adjust. Instead one can compute the p-
value for each gene using a Poisson model for the probability of
observing Xd or more recurrent de novo events based on the gene’s
mutation rate. We will call such a test the De Novo Test. This test
automatically incorporates the number of families and a gene
specific mutation rate to determine the likelihood of recurrent de
novo events.
Model of de novo and inherited mutations in a family
design
TADA model is formulated for sequence data from individual
genes. Data for the model can come from sequences of trios
(unaffected parents and an affected child) and from cases and
controls. Given the information from a gene, namely the pattern of
de novo mutations and inherited, damaging variants in the affected
progeny, the goal is to relate the data with the underlying genetic
parameters such as the relative risk of the mutations. In the model,
we restrict the class of variation to rare and deleterious mutations
acting dominantly and assume subjects can be classified as
carrying one of two ‘‘alleles’’, those with a deleterious mutation
of this type (a) and those without (A). We put alleles in quotes
because, for example, we treat all LoF events in the same gene as a
single LoF ‘‘allele’’. Because severe mutations are generally present
at very low frequencies in the population (typically v:001), there
are effectively two possible genotypes per gene, AA and Aa. If we
let q=2 denote the allele frequency of a, then the frequencies of the
genotypes AA and Aa in the population are approximately 1{q
and q, respectively.
For a trio consisting of unaffected parents and an affected child,
there are four likely genotype combinations (Figure 2), of which
only three are informative: if both parents are homozygous, a
heterozygous child results from a de novo mutation; and if one
parent is heterozygous, the a allele is either transmitted or not.
Based on the de novo and transmitted alleles, we formulate a
likelihood model for the observed data. Let m denote the rate of
mutation for the gene being analyzed per generation and
Author Summary
The genetic underpinnings of autism spectrum disorder
(ASD) have proven difficult to determine, despite a wealth
of evidence for genetic causes and ongoing effort to
identify genes. Recently investigators sequenced the
coding regions of the genomes from ASD children along
with their unaffected parents (ASD trios) and identified
numerous new candidate genes by pinpointing sponta-
neously occurring (de novo) mutations in the affected
offspring. A gene with a severe (de novo) mutation
observed in more than one individual is immediately
implicated in ASD; however, the majority of severe
mutations are observed only once per gene. These genes
create a short list of candidates, and our results suggest
about 50% are true risk genes. To strengthen our
inferences, we develop a novel statistical method (TADA)
that utilizes inherited variation transmitted to affected
offspring in conjunction with (de novo) mutations to
identify risk genes. Through simulations we show that
TADA dramatically increases power. We apply this
approach to nearly 1000 ASD trios and 2000 subjects
from a case-control study and identify several promising
genes. Through simulations and application we show that
TADA’s integration of sequencing data can be a highly
effective means of identifying risk genes.
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chromosome; let c denote the genotype relative risk for the
genotype Aa; and let f and cf denote the penetrance of AA and
Aa, respectively. Let Xd , Xt and Xnt be the counts of each of the
three outcomes (de novo, transmitted and nontransmitted, respec-
tively), from a sample consisting of Nd families. These counts
approximately follow Poisson distributions (see Text S1 for
derivation): Xd*Pois 2mcNdð Þ, Xt*Pois qcNdð Þ, and
Xnt*Pois(qNd ).
For case-control data, counts of genotype Aa in Ncase cases and
Ncontrol controls follow a Poisson distribution with approximate
rate parameters qcNcase and qNcontrol, respectively (see Text S1).
From this structure it is apparent that the transmitted counts can
be viewed as a type of case-control data with sample size Nd .
Combining data, let X0 be the total number of Aa in the controls
plus the number of transmitted A variants, and let X1 be the total
number of Aa in the cases plus the number of transmitted a
variants. It follows that
Xd*Pois 2mcNdð Þ X0*Pois(qN0) X1*Pois qcN1ð Þ ð1Þ
for which N0~NcontrolzNd and N1~NcasezNd . The resulting
probability model has three parameters (m,q,c) per gene. For each
Figure 1. Properties of the Multiplicity Test. (A) The probability a risk gene has two or more de novo LoF mutations in N families (i.e., the power)
depends on the mutation rate m. Power per gene of the Multiplicity Test as a function of N is shown for 4 mutation rates, which were chosen based
on percentiles (25’th, 50’th, 75’th, 90’th) of the distribution of m obtained from the full gene set. (B) The expected number of risk genes discovered by
the Multiplicity Test at d~2 (red, solid) or 3 (blue, dashed) as a function of the sample size N . The barplot shows the FDR at d~2. The simulation
assumes 1000 diseases genes out of 18,000, each with relative risk c~20:2; these parameters were estimated in the section on Genetic Architecture
of ASD.
doi:10.1371/journal.pgen.1003671.g001
Figure 2. A probabilistic model for a family trio with an affected child. Genotype probabilities are computed as the marginal probability of
parental genotypes times the conditional probability of the child, given the parents. The parameters m and q represent the mutation rate, and the
population frequency of the Aa genotype, respectively. Phenotype probabilities for the child, given genotype, are a function of f0, the penetrance of
the AA genotype, and c the relative risk of the mutation a. Rate is the (approximate) rate of observing counts Xd , Xnt and Xt from the latter 3 types of
trios, respectively.
doi:10.1371/journal.pgen.1003671.g002
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gene, the mutation rate per gene (m) can be estimated from its
exonic length and nucleotide content [1] and hence this quantity
can be treated as known. The statistical problem for each gene is
to estimate q and then test if c~1.
Transmission And De novo Association test: TADA
We conjecture that a more powerful strategy to discover risk
genes from family data is to combine the information on de novo
and inherited mutations into an unified statistical framework,
such as the one we just proposed, which forms the basis for
TADA. TADA tests the hypothesis H0 : c~1 against the
alternative H1 : c=1. A traditional likelihood ratio test will
not work well in this setting because one or more of the counts
will be zero for many genes, leading to poor maximum
likelihood estimates for q and c. To circumvent this problem
we cast TADA in a Hierarchical Bayes (HB) framework, thereby
improving estimates of q and c by pooling information across all
genes, but still modeling rates as gene-specific. The underlying
assumption is that LoF and severe missense mutations are rare
in all genes and hence we can learn about the frequency
distribution in a given gene by looking at the distribution across
all genes. Likewise, we can learn about how mutations in one
gene affect risk by examining the range and distribution of risks
across all disease-related genes.
The HB model assumes a fraction p of the genes are associated
with the disorder (model H1); the remaining fraction follow the
null model (model H0). Under H0, the relative risk is constrained
(c~1), but under H1, c is assumed to follow a distribution across
risk genes. For both models, the frequency of severe mutations per
gene, q, is assumed to vary by gene, with some commonality across
the genome. The distributions of c and q under both models are
specified by prior parameters, and we estimate the values of these
parameters by maximizing the marginal likelihood of the data (this
is known as the Empirical Bayes method, see Methods). Once the
prior parameters are estimated, we compute the evidence for H1
and H0 for each gene. Specifically, for the i-th gene, let xi be its
data, the evidence for H1 is defined as:
P(xi DH1)~
ð
p(xi Dqi,ci)p(qi DH1)p(ci DH1)dqidci ð2Þ
where p(xi Dqi,ci) is given by Equation 1, p(qi DH1) and p(ci DH1)
represent the prior distributions. Unlike the likelihood-based test,
the evidence for H1 is not based on point estimates of q and c;
instead it integrates out the two parameters. The model evidence
of H0 can be defined similarly, except that c is fixed at 1. The
Bayes factor of any gene is the ratio of P(xi DH1) to P(xi DH0). The
statistical significance of the Bayes factor is given by its p-value,
determined empirically by simulating data under the model
assuming c~1 (see Text S1).
Some insights into the relationship to a likelihood-ratio test
(LRT) can be gained by examining an approximation of B, the
Bayes factor:
B~
p(xi DH1)
p(xi DH0)
&
p(xi Dq^i(H1),c^i(H1))
p(xi Dq^i(H0),c~1)
ð3Þ
where the parameters are estimated by Bayesian mean posterior
estimators. These parameter estimates are a weighted average of
the maximum-likelihood estimate for the i-th gene and the mean
of the prior distributions. For example, q^i(H0) is interpolated
between the allele frequency derived from all genes and the gene-
specific estimate (Figure S1). Thus the Bayes factor is similar to the
LRT except that we utilize a refined estimator of the allele
frequency.
The model just described is designed for a single type of
mutation (say LoF), but it can incorporate multiple types. For
different types of mutations, such as LoF and damaging missense
mutations, the distributions of c and q are likely to be different, so
we model each type of mutation and estimate the prior parameters
separately using the HB framework. Then the total Bayes factor of
a gene is the product of the Bayes factor from each type of
mutation, and the p-value can be computed similarly from
simulations. In practice, we note that the damaging missense
mutations predicted by bioinformatic tools likely contain a number
of mutations having no effect on the gene function, thus we
introduce an additional model to account for this feature,
downweighting the evidence from missense mutations (see
Methods).
The TADA method we described can also be used for de novo
data alone. Basically, we ignore inherited and standing variants,
but allow multiple types of de novo mutations. The details are not
repeated here, but are provided in our supporting Website (see
Methods). We call this simplified model, TADA-Denovo, and it is
particularly useful for genes with multiple de novo events in different
categories (e.g. some nonsense and some missense mutations).
Genetic architecture of ASD
We use the proposed model to estimate the number of ASD risk
genes (k), their average relative risk (c), and the distribution of the
population frequency of the mutations. These estimates yield
insight into the genetics of ASD and pave the way for realistic
simulations to study the power of statistical tests. Our overall
strategy is first to use de novo mutations to estimate an approximate
range of the parameter values, then use the HB method to refine
these estimates using both family and the case-control data.
Consider the de novo LoF mutations in N~932 families [1–4].
These data reveal a total of C~123 de novo LoF mutations across
all genes, and M~5 multiple-hit genes (at least 2 independent de
novo LoF events per gene). Our goal is to find values of k and c that
best predict the observed counts C and M (Text S1). We assume
that the relative risk of an ASD risk gene varies across k genes,
with the average relative risk of the LoF mutations equal to c. The
mathematics of TADA reveal there is an inverse relationship
between k and c (Figure 3A, see Equation 27 in Text S1). For an
alternative and more intuitive explanation of why these param-
eters have an inverse relationship, see the arguments in [2]. For
any given value of k, we can compute the expected number of
multiple-hit genes; matching the expected with the observed value
of M, we estimate the the number of ASD risk genes is between
550 to 1000 (Figure 3B). In the next step, we use the HB model to
estimate the most likely value of k within this range, and the result
is k~1000 ASD risk genes, with the corresponding relative risk
c~20:2 (see Text S1). These estimates are similar to published
results using somewhat different methods [1,2].
We examine evidence for the hypothesis that the population
frequency of LoF mutations for ASD risk genes (q1) is lower than
that for non-risk genes (q0) because mutations in ASD risk genes
are under stronger negative selection than the average gene. These
frequencies are of interest because they have a major influence on
the power of association test [8]. We estimate q based on the
number of LoF variants in the case-control data from the AASC
[7] and the transmitted/nontransmitted data from 641 families
(the transmission data are only available for a subset of the 932
families). To obtain the empirical distribution of q across all genes
we first count the frequency of the LoF mutations in each gene
(Figure 3C); we find a substantial number of genes with 0 LoFs.
Model of De Novo and Inherited Variation
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We next estimate the prior distributions of q under the null and
alternative models, respectively, using the HB model and find they
provide a good fit to the observed data (Figure 3C, Figure S1).
From these analyses the mean of q under H1, i.e. the average q for
ASD risk genes, is about 3|10{5, significantly smaller than that
of non-risk genes, 6|10{4 (see Text S1 for a description of how
the HB model uses a mixture model to permit estimation of
parameters specific to ASD risk genes without actually classifying
genes as such.) Notably, while the empirical estimate of q for most
genes is 0 (thus not useful for inference), the value of q from the
HB model is never equal to 0 due to smoothing.
Using the same procedures we also estimated these param-
eters for missense mutations that are probably damaging
according to the PolyPhen prediction [9] (denoted as Mis3
mutations). Estimates reveal lower risk for these mutations, as
expected, and lower q for ASD risk genes compared with non-
ASD genes (Table S1).
Power analysis by simulation
Equipped with estimates of the genetic parameters, we can
simulate genetic data under the model and assess the performance
of statistical methods. We compare performance of three tests: De
Novo, as described in Section 2.1; TADA, described in Section 2.3;
and a ‘‘Meta test’’, which combines two tests, one based on de novo
events and the other on inherited variants, via meta analysis. For
the meta test we compute the p-value from data on inherited
variants using a Fisher exact test, treating transmitted/untrans-
mitted events as case-control data; and compute a p-value for de
novo events using the De Novo test. Then these p-values are
combined using Fisher’s method. In all the simulations, different
parameters are used to generate the data, yet TADA always uses
the same set of parameters derived from the real data, as described
previously. Thus these results establish the robustness of TADA
under different parameter settings and thus, to some extent, how it
should behave for real data.
Because TADA is a novel method, data were first simulated
under the null hypothesis of no association to obtain the
distribution of the TADA test statistic and its associated p-values.
The results show that the test is well calibrated and type I error is
properly controlled (Figure S2).
Next, data were simulated under the alternative model, using
different sample sizes and different combinations of the parameters
q and c, within the range of plausible values estimated in the
previous section. This comprehensive simulation showed TADA
has superior power relative to the other two tests (Figure S3). In
Figure 4, we show a selected portion of the simulation results
under the most likely scenarios, reflecting the trade-off between
relative risks and allele frequencies, i.e. mutations with high risks
are likely to exist in lower frequencies in the population. For a gene
with typical parameter values (Figure 4B), the power of the TADA
test, at N~5000, was about fivefold larger than that of the other
two tests.
To assess the performance of the tests from a genome-wide
analysis, we generated realistic simulated counts based on the
estimated genetic parameters for ASD, namely average relative
risk of 20 and k~1000 risk genes, among a total of 18,000 genes
sequenced. We focus on false discovery rate (FDR), calibrating the
empirical FDR to control at 10%, and estimated power as the
number of true discoveries. Results confirmed the advantage of
TADA (Figure S4A). For example, at N~5000, TADA identified
more than 200 ASD risk genes at FDR below 10%, while the De
Novo and Meta tests identify about 50 and 70 genes at this level of
FDR, respectively (cf Figure 1). We performed additional
simulations with somewhat different procedures to demonstrate
the robustness of these findings. In one experiment, we simulated
data under the average relative risk of 10, instead of 20, while
TADA still uses the relative risk of 20. The power of all methods
was significantly reduced, as expected, yet TADA still performed
better than both de novo test and the simple meta-analysis (Figure
S4B). In another experiment, the simulation procedure incorpo-
rated the possible dependency between the LoF frequency of a
gene (q) and its relative risk (c), based on simple mutation-selection
balance: the two were not sampled independently, but rather the
frequency was inversely proportional to the risk (see Methods).
Despite this change of simulation model, the results were virtually
identical to those from earlier simulations (Figure S4C).
Figure 3. The genetic parameters of ASD. (A) The relationship between the number of ASD risk genes (k) and the average relative risk (c). m
stands for the total number of genes in the human genome, and n for the fold enrichment of the de novo LoF mutations in probands vs. siblings
(about 2 in our data). (B) The expected number of multi-hit genes (M) in N~932 families, as a function of the number of ASD risk genes (k). The
observedM is 5, and we define the plausible range of k as the values corresponding toM~4 to 6. The model assumes the relative risks of ASD risk
genes follow a gamma distribution with the scale parameter b. The variance of the relative risk (c) across genes equals c=b2 (c is the average of c of all
ASD risk genes), which limits the range of plausible values for the model. The estimated value of the average c is approximately 20. (C) For each gene,
we compute the empirical allele frequency (q^) of LoFs as the number of LoF variants divided by the sample size. The histogram of the LoF frequencies
of all genes is shown. Also shown are the estimated distributions of q under the null (red, solid line) and the alternative (blue, dashed line) models,
respectively.
doi:10.1371/journal.pgen.1003671.g003
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Analysis of data to identify genes affecting the risk of
ASD
The data we used were all reported de novo mutations from 932
ASD families [1–4]; transmitted mutations from 641 of these
families; and case-control data from the AASC, consisting of 935
ASD subjects and 870 controls [7]. Each missense mutation was
classified into a category of damage to the protein based on its
predicted effect on the coding sequence using PolyPhen2 [9]:
benign (Mis1); possibly damaging (Mis2); and probably damaging
(Mis3). Note that de novo LoF mutations occurred at about two-fold
enriched rate in the probands relative to the unaffected siblings
(Figure 5A, Table S2). The rate for de novo Mis3 was also higher in
probands than siblings, but the difference was not as striking.
There is essentially no difference in probands and siblings for other
types of mutations. We thus applied the TADA method to the LoF
and Mis3 mutations.
The overall inflation of the results due to population stratifica-
tion is negligible: a modified [7] genomic control factor [10]
lq~1:02 (see Text S1). There is significant enrichment of genes
with low p-values compared with random expectation (Figure 5B):
244 genes have p{valuev0:01, 64 more than expected under the
null model. There is an intriguing coincidence in the excess of
small p-values - namely that it is very similar to the excess number
of genes with single-hit de novo LoF events in ASD subjects
Figure 4. The power per gene of competing tests. The results of three tests are shown: novo (red), meta (blue), and TADA (purple). Results are
shown for various values of N , c and q with type I error fixed at 0.001. Parameter values are chosen to cover plausible parameter values according to
our model estimation: (A) c~15,q~1|10{4 ; (B) c~20,q~5|10{5 ; and (C) c~25,q~2:5|10{5 .
doi:10.1371/journal.pgen.1003671.g004
Figure 5. Application of TADA to the genetic data of ASD. (A) De novo LoF and ‘‘probably damaging’’ missense mutations are enriched in ASD
probands (red) compared with unaffected siblings (blue), based on a comparison including all trio and quad families. The other types of missense
mutations are not enriched. To make the numbers comparable, the number of mutations in siblings is scaled by a constant multiplier (214/124) so
that the numbers of silent mutations is equal in probands and in siblings. The annotations of missense mutations are based on PolyPhen. (B) Q-Q plot
(log. scale) of the p values for all genes in the ASD dataset based on a combined analysis of LoF and severe missense mutations.
doi:10.1371/journal.pgen.1003671.g005
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compared to their unaffected siblings [1]. Notably the large tail in
the QQ plot is largely driven by the de novo LoF events, and
appears to reflect true signal instead of inflation.
We control for the multiple hypothesis testing using the
Benjamini-Hochberg procedure [11]. Fifteen genes meet the
criteria of a False Discovery Rate less than 20% (Table 1, see
Table S3 for the complete results). The list includes all five genes
with two de novo LoF mutations, as well as several novel genes that
are promising candidates for ASD based on existing evidence. For
the novel predictions, the p-values from the de novo data alone are
far from achieving genome-wide significance (the pdn column in
Table 1) and would be impossible to identify without combining
the de novo, transmitted and case-control data.
The results of TADA generally depend on the estimates of the
mutation rates of the genes, as well as the Bayesian prior
parameters of the model. We perform additional analyses to study
how sensitive the results are to these parameters. Based on our
findings, we choose several genes from Table 1 for this
investigation. Although the error of mutation rate estimation is
likely small [1], we vary the mutation rate of each gene: from 1/2
of the estimated rate to twice the rate. As expected, the p-value
increases as the mutation rate increases, although overall the
impact is modest (Figure S5A). Next we vary the Bayesian prior
parameter, c, which represents the average relative risk over all
risk genes, from 10 to 20. The p-values from TADA are even less
sensitive to this parameter (Figure S5B).
Table 1. Top predicted ASD risk genes from the TADA analysis of combined ASD data (de novo, inherited and case-control).
Loss of function (LoF)
Gene De novo Transmitted Nontransmitted Case Control pdn pTADA(LoF)
KATNAL2 2 1 0 4 0 3.161026 261027
CHD8 2 0 0 3 0 9.561025 2.461026
LMCD1 0 2 0 0 0 1 0.067
S100G 1 0 0 3 0 0.00042 1.661025
DYRK1A 2 0 0 0 0 8.661026 4.361026
PPM1D 1 0 0 2 0 0.0032 0.00023
SCN2A 2 0 0 0 0 5.961025 2.861025
CUL3 1 0 0 3 0 0.004 0.00013
DEAF1 0 2 0 1 0 1 0.031
BANK1 0 1 0 4 0 1 0.0064
POGZ 2 0 0 0 0 361025 1.461025
WDR55 0 1 0 0 0 1 0.18
FAM91A1 1 0 0 0 0 0.0046 0.0019
COL25A1 1 0 0 5 0 0.0034 2.361025
Probably damaging (Mis3)
Gene De novo Transmitted Nontransmitted Case Control pTADA
KATNAL2 0 2 3 4 5 1.561026
CHD8 0 4 6 9 9 1.361025
LMCD1 0 4 0 9 0 1.761025
S100G 0 0 0 0 0 2.161025
DYRK1A 0 0 4 4 1 5.661025
PPM1D 0 0 0 2 0 7.961025
SCN2A 1 8 7 5 5 8.461025
CUL3 0 0 0 1 0 8.661025
DEAF1 0 1 0 8 0 0.0001
BANK1 0 7 0 6 2 0.00011
POGZ 0 4 1 3 5 0.00012
WDR55 1 0 0 6 0 0.00012
FAM91A1 0 12 1 2 2 0.00016
COL25A1 0 5 3 4 4 0.00016
The pdn column shows the p-values using the De Novo Test from the de novo LoF mutations alone. The pTADA(LoF) column shows the p-values from the TADA test using
all LoF data. The pTADA column shows the p-values from the TADA test using both LoF and Mis3 data. The star symbols mark the double-hit genes that were reported in
earlier publications. C1orf95 also has q-value,.2, however this signal is based entirely on 11 identical Mis3 variants in cases and 0 in controls. This allele is common in
African populations [40]. While the AASC sample is of European ancestry, a portion of it, largely from Portugal, carries some sub-Saharan alleles [7]. Thus, this signal is
likely due to population substructure. Similarly, the 3 LoF variants seen in S100G are copies of a splice variant that is common in African populations, so this result
should be viewed with caution.
doi:10.1371/journal.pgen.1003671.t001
Model of De Novo and Inherited Variation
PLOS Genetics | www.plosgenetics.org 7 August 2013 | Volume 9 | Issue 8 | e1003671
Discussion
For disorders like ASD, recent results show that detection of de
novo LoF events can be a powerful means of discovering novel risk
genes [1–4]. Yet de novo events are relatively rare, roughly one per
exome, and de novo LoF events even more so, and thus many
families must be assessed to identify multiple de novo LoF events in
the same gene. To make the most of this experimental design, we
develop a new statistical approach, TADA, that utilizes both
transmitted and de novo variants from nuclear families and case-
control data to determine genetic association. TADA builds on the
simple multiplicity test, which relies on recurrent de novo events, but
it creates a full analytical framework to incorporate all of the
information on the distribution of rare variation. The result is a
test with greater power. Our test achieves its good performance
properties by providing an analytic framework that links the
observed pattern of de novo mutations with the underlying genetic
parameters, such as the relative risk conveyed by such mutations.
In addition to analyzing data for novel gene discovery, this
framework can be used to analyze the power of a test and predict
the required sample size to attain sufficient power for future
investigations. Moreover, by using empirical Bayes methods,
TADA refines estimates of allele frequencies of the damaging
mutations by using the full genome to estimate these quantities.
This approach increases the information in the transmitted
variants in each gene considerably and yet maintains good control
of false discoveries.
Association studies evaluating cases and controls have been a
common design for identifying variation affecting risk for complex
diseases. It has proven successful for identifying common variation
affecting risk, after sufficient samples had been amassed to ensure
variation having modest impact on risk could be detected [12].
Common variants surely play a role in ASD [13,14], but the effect
sizes are small [15] and it will be challenging to detect individually-
significant SNPs. Indeed virtually every discovery for ASD risk
genes traces to rare and de novo variants [1–4,16–20].
As the cost of sequencing drops, genetic research increasingly
focused on the role of rare variants in complex diseases such as
ASD, but the sample size has been limited and so has the yield
of such studies. For a sample of nearly 1000 ASD case and well
matched controls the ARRA ASD sequencing consortium
(AASC) found no significant associations [7], except for
variation acting recessively [6]. These results comport with
studies of other disorders and suggest that large sample sizes will
be required to achieve good power in rare variant association
studies [21]. Arguably a fundamental difficulty is that most of
the mutations with large effects tend to be under strong negative
selection, existing at very low frequencies in the population [22].
Variants that occur with greater frequency often have smaller
effect on the phenotype, reducing the power of gene-based test
statistics.
Our analysis provides insight into some advantages of de novo
over case-control studies, especially for LoF events. The de novo test
gains power because the mutation rate for genes can be estimated
accurately from supplementary sources, and need not be estimated
as part of the statistical procedure. Because of the low mutation
rate, the number of de novo LoF events expected by chance is very
small, and thus we could attach high statistical significance to any
gene with more than one independent LoF mutation. While a
single de novo LoF event is certainly not definitive evidence, it can
put a gene on the short list as a risk gene – for ASD, it is more
likely than not an ASD risk gene. In contrast, for case-control data,
we require an estimate of the allele frequency q under the null
hypothesis. When the mutant allele is very rare (as for ASD risk
genes), a very large sample is required to ensure that this frequency
is indeed small.
Another feature of observed de novo mutations is that they have
not been subject to the force of purifying selection, which plays a
key role in shaping the pattern of standing variation. Therefore it
is likely that de novo mutations, especially LoF mutations, have
stochastically larger effect sizes than rare variation transmitted for
generations, because selection tends to drive down allele frequen-
cies of variants having large effects on reproductive success.
Moreover, allele frequency is inversely tied to power, critical for
any experimental design. Therefore studies utilizing de novo
variation can have distinct advantages, in terms of power, relative
to those that do not.
By simulations we demonstrate that the power of TADA is
higher than tests based solely on de novo events or standard meta-
analysis that combines p-values from de novo and inherited data
(transmission or case/control). There are two explanations for this
gain of power. First, TADA’s hierarchical model uses the
information in the case-control (or transmission) data more
efficiently than the standard hypergeometric or trend test. One
important property of LoF mutations, compared to less severe
functional variants, is their rarity in the population (Figure 3C).
TADA, which is similar in spirit to a Poisson test of rare events, is
able to exploit the rarity of these damaging events by estimating
the distribution of LoF alleles across the exome (see Figure S1B),
whereas the other methods cannot. Second, because damaging de
novo mutations are rare, most genes will not harbor them even
when thousands of cases have been sequenced. For such genes,
using Fisher’s method to combine the de novo p-value, which will be
close to 1, with the p-value from the case-control data penalizes the
overall test statistic. In contrast, the Bayesian approach uses de novo
events when they are informative and disregards the de novo data
when they are uninformative; the Bayes factor from de novo in such
cases would be close to 1, making little contribution to the gene’s
total Bayes factor.
We estimate that there are about 1,000 ASD risk genes with
average relative risk about 20. In a recent paper using the same de
novo data, the number of ASD risk genes (k) was estimated at 370
[4]. In that paper, the expected number of genes with recurrent
LoF events was derived as a function of k, and equating it to 5 (the
observed number), produced the solution that k~370. The
analysis made the implicit assumption that all ASD risk genes are
equally likely to sustain multiple de novo LoF events. In Text S1 we
show, using Jensen’s Inequality, that the non-uniform distribution
of the mutation rates and the relative risks among the ASD risk
genes leads to a significant under-estimation of k, explaining the
discrepancy between our results and those of Iossifov et al. [4].
When applied to ASD data, TADA predicts a number of novel
ASD risk genes (Table 1), as well as supporting results for known
ASD risk genes. For some of the newly implicated genes it is
straightforward to garner other supporting evidence for their role
in ASD. S100G is a downstream target of CHD8, a key
transcriptional regulator often disrupted in ASD subjects [23].
CUL3 plays a critical role in neurodevelopment [24,25] and in
particular regulates synaptic functions [26]. A recent study
identified an additional de novo protein-changing mutation in
CUL3 in ASD probands [27], replicating our finding here.
COL25A1, a brain-specific collagen, was implicated in risks for
Alzheimer’s disease [28] and antisocial personality disorder [29].
Inspection of other genes slightly below our chosen FDR
threshold reveals several more interesting genes that likely play
some role in ASD (all ranked among the top 25, see Table S3).
TBR1, a transcription factor critical in brain development,
regulates several known ASD risk genes [30]. A recent study has
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identified recurrent de novo disruptive mutations in TBR1 in ASD
subjects [23]. MED13L, a component of the Mediator Complex, is
intriguing because of its role in Rb/E2F control of cell growth [31]
and the fact that RB/E2F plays a key role in neurogenesis [32]
and neuronal migration [33]. Recently MED13L has been
associated with risk for schizophrenia [34]. NFIA is a member of
the NFI transcription factor family, thought to have a neuropro-
tective role [35], and NFIA-knockout mice display profound
defects in brain development [36].
Genotyping/sequencing errors can introduce biases in data
analyses, especially those for family data [37,38] and for
combining data across multiple heterogeneous studies [39]. Our
analyses are likely robust to these possible biases because the
variant calls were all carefully evaluated: (i) all de novo mutations
described previously [1–4] and analyzed here, a total of 122 LoF
and 314 damaging missense mutations, have been validated by
previous studies; (ii) the case-control data have been carefully
harmonized to minimize batch effects by using stringent quality
control filters [7]; and (iii) for the case-control data, all variant calls
in two genes (CHD8 and SCN2A) have been evaluated by Sanger
sequencing and 20 out of 20 validate, further supporting the
quality of the variant calls in the case-control data. When the
sensitivity of calling minor variants is low (under-calling), this may
create an under-transmission bias in family-based test statistics;
however, TADA is effectively a one-sided test of the adverse effect
of the minor allele. As such, TADA is only powered to detect risk
variants that are over-transmitted and thus bias due to under-
transmission is not a significant concern. Nonetheless, data quality
is always an important concern, and can change over time in
subtle ways [37,38], making high-quality filters and validation of de
novo events critical for good data analyses. It is possible that TADA
would benefit by modeling measurement errors and this will be a
topic for future research, when the error structure in the data is
better understood.
While much of our focus has been on ASD data and the genetic
architecture of ASD, TADA has utility beyond the genetics of
ASD. For example, we would expect TADA to be useful for gene
discovery by the analysis of data from any genetic disorder or
disease for which de novo mutations play a substantive role in risk.
Early onset diseases and disorders are obvious candidates for the
use of TADA, as are disorders such as schizophrenia and
congenital heart disease. Indeed there are a plethora of human
diseases for which de novo mutations account for at least a small
fraction of risk, even diseases that onset in mid-life such as
cardiovascular disease. Because TADA is based on a general
theoretical framework for combining rare variation found in exons
of genes, we predict that its logic can have even broader
applications than simply the analysis of single genes for their
association with disease.
Methods
Sequence data
We combined exome sequence data from four recent studies of
ASD, covering 932 families [1–4]. Detailed information about
study design, including family structure (simplex versus multiplex),
ascertainment, and DNA source (blood versus cell line), can be
found in the Supplements of these papers. The de novo mutations,
including both single nucleotide variants (SNVs) and indels, were
identified as described in the original papers. The transmitted and
non-transmitted variants were extracted from 641 of these families
(see Text S1 for details on data processing). We excluded all
common variants from the analysis, defined as those present at
w1% population frequency in the Exome Sequencing Project
(ESP) controls and/or the 1,282 parents [40]. Only SNVs were
called for the transmission data, indels were not identified. We also
included case/control data from the ARRA ASD Sequencing
Consortium, consisting of 935 ASD subjects of European ancestry
and 870 controls of ancestry similar to cases, selected from the
NIMH repository (see complete information on study design in the
supplement of Liu et al [7]). The SNVs and indels in the case/
control were called as described in [7]. Each mutation/variant in
the combined data was classified into different categories, based on
its predicted effect on the protein function, according to the
program PolyPhen2 [9]. In this study we focused on (1) LoF
mutations, defined as nonsense mutations, mutations in splice sites
or frameshift indels; and (2) mutations classified as ‘‘probably
damaging’’ to protein function by PolyPhen2 (Mis3). We also
removed all genes with more than 10 LoF events in the control
samples (166 genes in total) from the analysis, as these genes are
unlikely to be related to ASD.
Mutation rate estimation
For each gene, the total rate of base pair substitutions was
estimated using a probability model taking the gene length and
base content into account [1]. To estimate the rate of a specific
type of mutation (LoF or Mis3) of a gene, we multiplied the gene-
level mutation rate and the proportion of that type of mutation.
The proportion of LoF or Mis3 mutations was estimated from the
data of unaffected siblings in the ASD families (Table S2). In these
siblings, there were 461 single-nucleotide variants (SNVs) and 34
LoF variants, thus the LoF fraction was 34=461~0:074. Similarly
the Mis3 fraction was calculated as 147=461~0:32.
TADA model and the statistical test
Two hypotheses were compared, H1 : ci=1 versus H0 : ci~1,
for each gene. For most genes, the number of LoF mutations either
transmitted or not (or in cases and controls) was generally very
small and often 0, leading to a naive estimate of q^~0 and creating
a challenge for a likelihood-based test. To refine inference we took
an Empirical Bayes approach and developed a hierarchical Bayes
model for the data (Figure 6). We estimated the prior parameters
in the model by maximizing the marginal likelihood. The
hierarchical model assumed a fraction p of the genes was
Figure 6. Bayesian hierarchical model of TADA. A fraction p of
the genes are associated with the phenotype under investigation and
follow model H1 , and the remainder follow model H0 . The prior
distribution of gene-specific parameters, relative risk (ci) and allele
frequency (qi), can vary under the competing models, H1 or H0.
Priors are specified by the hyperparameters, w1 and w0 , respectively,
which are estimated from the data. Counts of events for the i-th gene
follow a Poisson distribution, parameterized by ci and qi under H1,
and qi under H0 .
doi:10.1371/journal.pgen.1003671.g006
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associated with the disorder (modelH1) and the remaining fraction
followed the null model (H0). Under H0, we assumed c~1 for all
genes and q followed a Gamma(q0n0,n0) distribution (we
parameterized the distribution so that its mean was q0). The
scaling parameter of the Gamma distribution (n0) played the role
of a precision parameter or pseudo count; the bigger n0 the more
similar q was estimated to be across genes. Under H1, we assumed
ci of the i-th risk gene follows a Gamma(cb,b) distribution and qi
follows a Gamma(q1n1,n1) distribution.
Let w1~(c,b,q1,n1) be the prior parameters of H1, and
w0~(q0,n0) be those of H0 (they are also called hyperparameters).
The counts for the i-th gene, xi~(x
1
i ,x
0
i ,x
d
i ), follow Poisson
distributions parameterized by ci (1 for non-risk genes) and qi, as
defined in Equation 1.
The marginal likelihood of the i-th gene under either model,
P(xi DH1) and P(xi DH0), is given by:
P(xi DH0)~
ð
p(xi Dqi,ci~1)p(qi DH0)dqi, ð4Þ
P(xi DH1)~
ð
p(xi Dqi,ci)p(qi DH1)p(ci DH1)dqidci: ð5Þ
The marginal likelihood of all the data, as a function of the
hyperparameters (w1,w0), is
P(xDw,w0)~ P
n
i~1
pP(xi DH1)z(1{p)P(xi DH0)½ : ð6Þ
We assume the proportion of risk genes, p, is known (in our
analysis of ASD data, this is obtained by the estimated value of k,
the number of ASD risk genes, see Section 2.4). The hyperpara-
meters can then be found by maximizing this marginal likelihood
function. Once we have the estimated values of w1 and w0, we
compute the Bayes factor of any gene:
Bi~
P(xi DH1)
P(xi DH0)
: ð7Þ
The p-values of the observed Bayes factors are calculated by
sampling the null distribution according to Equation 1 (see Text
S1).
TADA for multiple types of mutations
When analyzing multiple types of mutations (LoF and Mis3 in
our analysis of ASD data), we assumed the data for each type of
mutation were independent of each other, and hence we estimated
the prior parameters for each type of mutation separately. The
Bayes factor of a gene is defined as the product of the Bayes factor
for each type of mutation. For these ASD data, the Mis3 mutations
are likely to be a mixture of those causing protein-damaging
changes and those having no real effects on the protein function.
We thus computed the joint Bayes factor of the gene using this
equation:
B~BLoF½w :BMis3z(1{w); ð8Þ
we used w~0:55 in our ASD analysis (see Text S1).
Simulation procedure
Our simulation procedure generated data using the estimated
genetic parameters of the LoF mutations of the ASD risk genes
(Text S1). For our initial simulations, we compared the power of
several statistical tests, at the single gene level, under various
combinations of parameter values. We set the mutation rate as
the mean mutation rate of the LoF mutations of all human
genes, 1:7|10{6. The parameters c and q were chosen
according to their estimated mean values: c~15,20,25, and
q~5|10{5,1|10{4,2|10{4. We compared the power of the
three tests under type I error 0.001.
For the second set of simulations, we assessed the performance
of the three tests in the genomewide setting. Specifically, from
among 18,000 genes in the human genome, we first randomly
sampled k~1000 risk genes and the rest were assumed to be
unrelated to disease (we used the estimated mutation rates of all
genes to make this simulation realistic). For a risk gene and a LoF
mutation, the effect size parameter c was sampled from the
distribution c*Gamma(20,1). Its population frequency parame-
ter q was sampled from the distribution, Gamma(0:5,10000). For
a non-causal gene, its relative risk c~1, and the frequency
parameter q was sampled from the distribution Gamma(0:5,500).
The simulation procedure then generated, for each gene, the
number of de novo mutations (Xd ), the number of transmitted
variants (X1) and the number of nontransmitted variants (X0),
according to Equation 1.
We ran the three statistical tests, as described in the text, on the
simulated data from all genes. At various significance levels, we
calculated the number of true discoveries (M1), i.e. the number of
diseases genes whose test statistic reached significance level a. We
chose the value of a so that FDR is less than 0.1, and reportedM1
at this value of a (see Text S1 for our procedure for controlling
FDR in the simulations.)
In additional simulations, we varied the basic procedure just
described. In one setting, the average relative risk was set to 10
instead of 20, i.e., c of a risk gene was sampled from the
distribution Gamma(10,1). In another setting, instead of sampling
q and c of each risk gene independently, we modeled the two as
dependent. Specifically, for the i-th risk gene, let ci and qi be the
relative risk and the LoF frequency, respectively. First sample ci
from Gamma(20,1), then determine qi according to a simple
mutation-selection balance: qi~mi=d, in which mi is the mutation
rate and d is a constant. To determine the value of d, we plugged
in the mean values of q, m and c in the above equation and solve
d~0:0017.
Software
TADA software is available as an R package at http://wpicr.
wpic.pitt.edu/WPICCompGen/. The package also includes
TADA-Denovo, the simplified version of TADA, that analyzes
only de novo data.
Supporting Information
Figure S1 Bayesian estimation of the frequency parameter q. (A)
The observed LoF counts (red) of all genes, vs. the simulated
counts (blue). For simulation of one gene, we first sample q from
the estimated prior distribution of q under H0, and then generate
the count data under this q according to the Poisson model
(Equation 1 of the text). The procedure is repeated for all genes,
and the resulting barplot is provided along with the distribution of
the observed data. Note that we did not use the distribution qDH1,
as most of the genes are not disease-related. (B) The Bayesian
hierarchical model estimation of the allele frequency q of LoF
variants. The blue circles show the observed frequencies of 10
different genes, which are also maximum likelihood estimates
(MLE). The red circle shows the average q over all genes (prior
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mean). The Bayesian posterior mean estimates are the weighted
average of the MLE and the prior mean (the intersection of the
dashed line and solid lines), with weight w (0.20 in this example).
(TIF)
Figure S2 Typical Q-Q plots under the null distribution of the
TADA test statistic. We simulate n~10000 genes under the null
model, with mutation parameter m~1:7|10{6 (the mean LoF
mutation rate of all human genes), and q varying from from
3|10{4 to 3|10{3 (the average q of non-autism genes is about
0.001) and number of family trios (N) varying from 1000 to 3000.
The TADA model is applied to each of 9 simulated datasets to
obtain the p-values and resulting Q-Q plots. Although there is
normal variation in these samples, most follow the expected null
distribution fairly closely.
(TIF)
Figure S3 The power of the de novo test (red), the meta test (blue)
and TADA (purple) at type I error 0.001, under various values of
N , c and q.
(TIF)
Figure S4 The number of discovered disease genes as a function
of sample size at FDR equal to 10%. We compare power for a test
relying on only de novo events (De novo Test, red), a test combining p-
values from de novo and transmitted data by Fisher’s method (Meta
test, blue), and the joint likelihood-based analysis (TADA test,
purple). Results from three different simulations are shown. (A)
Simulation using the estimated ASD parameters (the average
relative risk c~20). (B) Simulation assuming c~10. (C) Simulation
under the inverse-relationship between the LoF frequency (q) and
the relative risk (c) for each risk gene.
(TIF)
Figure S5 Sensitivity analysis of TADA for four selected genes.
(A) For each gene, suppose m is its (estimated) mutation rate, we let
TADA use a different rate, ranging from m=2 to 2m, and the
resulting p-values are shown. (B) We vary the prior parameter c
(the average relative risk of all risk genes) of TADA from 10 to 20,
and compute the TADA p-values.
(TIF)
Table S1 Parameters from Hierarchical Bayes estimation. The
LoF and damaging missense (Mis3) mutations of ASD genes have
high relative risks, and appear to be under stronger purifying
selection than non-ASD genes.
(PDF)
Table S2 The statistics of the de novo mutations in autism
probands and unaffected siblings. The missense labels are based
on predictions from PolyPhen2. Missense1–3 correspond to
‘‘benign’’, ‘‘possibly damaging’’ and ‘‘probably damaging’’
mutations, respectively. The last row is the counts of frameshift
indels.
(PDF)
Table S3 The complete prediction results of TADA. The
‘‘mut.rate’’ column shows the estimated mutation rate of the
genes. For each of the two types of mutations, LoF and mis3
(severely damaging), five counts are shown, including the number
of de novo mutations, the numbers of transmitted and non-
transmitted variants, and the number of variants in cases and
controls. The pdn column shows the p-values using the De Novo Test
from the de novo LoF mutations alone. The pTADA(LoF) column
shows the p-values from the TADA test using all LoF data. The
pTADA column shows the p-values from the TADA test using both
LoF and Mis3 data. The last column shows the q-value of pTADA
after Benjamini-Hochberg correction of multiple testing.
(XLSX)
Text S1 Supplementary methods explaining the details of
TADA, and our analysis of ASD data.
(PDF)
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